Prudence Francis

DE NOVO VS RECURRENCE ADVANCED BREAST CANCER

Prudence A Francis

Conference Proceedings  |  2019  |  The Breast

Adjuvant endocrine therapy for premenopausal women: risk stratification, type and duration

Prudence A Francis

Journal article  |  2019  |  The Breast

Updated results from the Suppression of Ovarian Function Trial (SOFT) and Tamoxifen and Exemestane Trial (TEXT) have helped to ide..

De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017.

G Curigliano, HJ Burstein, E P Winer, M Gnant, P Dubsky, S Loibl, M Colleoni, MM Regan, M Piccart-Gebhart, H-J Senn, B Thürlimann, undefined Panel Members of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017

Journal article  |  2019  |  Annals of Oncology

Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial

Karin Ribi, Weixiu Luo, Marco Colleoni, Per Karlsson, Jacquie Chirgwin, Stefan Aebi, Guy Jerusalem, Patrick Neven, Vincenzo Di Lauro, Henry L Gomez, Thomas Ruhstaller, Ehtesham Abdi, Laura Biganzoli, Bettina Mueller, Annelore Barbeaux, Marie-Pascale Graas, Manuela Rabaglio, Prudence A Francis, Theodoros Foukakis, Olivia Pagani, et al.

Journal article  |  2019  |  British Journal of Cancer

Adjuvant Systemic Treatment of Premenopausal Women With Hormone Receptor-Positive Early Breast Cancer: Lights and Shadows

Meredith M Regan, Gini F Fleming, Barbara Walley, Prudence A Francis, Olivia Pagani

Journal article  |  2019  |  Journal of Clinical Oncology

Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials.

undefined Early Breast Cancer Trialists' Collaborative Group (EBCTCG)

Journal article  |  2019  |  The Lancet

BACKGROUND: Increasing the dose intensity of cytotoxic therapy by shortening the intervals between cycles, or by giving individual..

Implementation of a Multidisciplinary Model of Care for Women With Metastatic Breast Cancer: Challenges and Lessons Learned

Sarah-May Blaschke, Karla C Gough, Boon H Chua, Prudence A Francis, Robyn Cockerell, Allison F Drosdowsky, Lisa Sheeran, Meinir Krishnasamy

Journal article  |  2019  |  Clinical Breast Cancer

Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers

Sherene Loi, Damien Drubay, Sylvia Adams, Giancarlo Pruneri, Prudence A Francis, Magali Lacroix-Triki, Heikki Joensuu, Maria Vittoria Dieci, Sunil Badve, Sandra Demaria, Robert Gray, Elisabetta Munzone, Jerome Lemonnier, Christos Sotiriou, Martine J Piccart, Pirkko-Liisa Kellokumpu-Lehtinen, Andrea Vingiani, Kathryn Gray, Fabrice Andre, Carsten Denkert, et al.

Journal article  |  2019  |  Journal of Clinical Oncology

Phase 1 trial of olaparib and oral cyclophosphamide in BRCA breast cancer, recurrent BRCA ovarian cancer, non-BRCA triple-negative breast cancer, and non-BRCA ovarian cancer

Chee Khoon Lee, Clare Scott, Geoffrey J Lindeman, Anne Hamilton, Elizabeth Lieschke, Emma Gibbs, Rebecca Asher, Heath Badger, Robin Paterson, Lauren Macnab, Edmond Michael Kwan, Prudence A Francis, Frances Boyle, Michael Friedlander

Journal article  |  2019  |  British Journal of Cancer

Final Analysis of the Prevention of Early Menopause Study (POEMS)/SWOG Intergroup S0230

Halle CF Moore, Joseph M Unger, Kelly-Anne Phillips, Frances Boyle, Erika Hitre, Anna Moseley, David J Porter, Prudence A Francis, Lori J Goldstein, Henry L Gomez, Carlos S Vallejos, Ann H Partridge, Shaker R Dakhil, Agustin A Garcia, Julie R Gralow, Janine M Lombard, John F Forbes, Silvana Martino, William E Barlow, Carol J Fabian, et al.

Journal article  |  2019  |  JNCI: Journal of the National Cancer Institute

Immune parameters associated with survival in triple negative and HER2-positive breast cancer patients with 10 years of follow-up

C Solinas, A de Wind, G Van den Eynden, L Ameye, S Garaud, P De Silva, A Boisson, G Noel, M Langouo Fontsa, L Buisseret, E de Azambuja, PA Francis, A Di Leo, JP Crown, C Sotiriou, D Larsimont, M Paesmans, M Piccart-Gebhart, K Willard-Gallo

Conference Proceedings  |  2019  |  Poster Discussion Abstracts

Adjuvant Endocrine Therapy for Premenopausal Breast Cancer REPLY

Prudence A Francis, Olivia Pagani, Meredith M Regan

Journal article  |  2018  |  NEW ENGLAND JOURNAL OF MEDICINE

Postmastectomy Radiation Therapy Omission in the Taxanes-based Chemotherapy Era for Patients With One to Three Positive Nodes: "Better Safe Than Sorry!" Reply

Youssef H Zeidan, Joyce G Habib, Evandro de Azambuja, Ian Campbell, Michael Andersson, Ana Lluch, Angelo Di Leo, Prudence A Francis

Journal article  |  2018  |  International Journal of Radiation Oncology*Biology*Physics

De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017.

G Curigliano, HJ Burstein, EP Winer, M Gnant, P Dubsky, S Loibl, M Colleoni, MM Regan, M Piccart-Gebhart, H-J Senn, B Thürlimann, F André, J Baselga, J Bergh, H Bonnefoi, SY Brucker, F Cardoso, L Carey, E Ciruelos, J Cuzick, et al.

Journal article  |  2018  |  Annals of Oncology

4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)

F Cardoso, E Senkus, A Costa, E Papadopoulos, M Aapro, F Andre, N Harbeck, B Aguilar Lopez, CH Barrios, J Bergh, L Biganzoli, CB Boers-Doers, MJ Cardoso, LA Carey, J Cortes, G Curigliano, V Dieras, NS El Saghir, A Eniu, L Fallowfield, et al.

Journal article  |  2018  |  Annals of Oncology

Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer

PA Francis, O Pagani, GF Fleming, BA Walley, M Colleoni, I Lang, HL Gomez, C Tondini, E Ciruelos, HJ Burstein, HR Bonnefoi, M Bellet, S Martino, CE Geyer, MP Goetz, V Stearns, G Pinotti, F Puglisi, S Spazzapan, MA Climent, et al.

Journal article  |  2018  |  New England Journal of Medicine

Postmastectomy Radiation Therapy in Women with T1-T2 Tumors and 1 to 3 Positive Lymph Nodes: Analysis of the Breast International Group 02-98 Trial

Youssef H Zeidan, Joyce G Habib, Lieveke Ameye, Marianne Paesmans, Evandro de Azambuja, Richard D Gelber, Ian Campbell, Bo Nordenskjold, Jorge Gutierez, Michael Anderson, Ana Lluch, Michael Gnant, Aron Goldhirsch, Angelo Di Leo, David J Joseph, John Crown, Martine Piccart-Gebhart, Prudence A Francis

Journal article  |  2018  |  International Journal of Radiation Oncology*Biology*Physics

Absolute improvements in freedom from distant recurrence with adjuvant endocrine therapies for premenopausal women with hormone receptor-positive (HR ) HER2-negative breast cancer (BC): Results from TEXT and SOFT.

Meredith M Regan, Prudence A Francis, Olivia Pagani, Gini F Fleming, Barbara Walley, Giuseppe Viale, Marco Colleoni, Istvan Lang, Henry Leonidas Gomez, Carlo Alberto Tondini, Graziella Pinotti, Angelo Di Leo, Alan S Coates, Aron Goldhirsch, Richard D Gelber

Conference Proceedings  |  2018  |  Journal of Clinical Oncology

Male breast cancer: pink ribbon blues.

PA Francis

Journal article  |  2018  |  Annals of Oncology

p-STAT3 in luminal breast cancer: Integrated RNA-protein pooled analysis and results from the BIG 2-98 phase III trial

Amir Sonnenblick, Roberto Salgado, Sylvain Brohee, Tamar Zahavi, Tamar Peretz, Gert Van Den Eynden, Ghizlane Rouas, Asher Salmon, Prudence A Francis, Angelo Di Leo, John PA Crown, Giuseppe Viale, Laura Daly, Bahar Javdan, Sho Fujisawa, Evandro De Azambuja, Ameye Lieveke, Martine J Piccart, Jacqueline F Bromberg, Christos Sotiriou

Journal article  |  2018  |  International Journal of Oncology

Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial.

Marco Colleoni, Weixiu Luo, Per Karlsson, Jacquie Chirgwin, Stefan Aebi, Guy Jerusalem, Patrick Neven, Erika Hitre, Marie-Pascale Graas, Edda Simoncini, Claus Kamby, Alastair Thompson, Sibylle Loibl, Joaquín Gavilá, Katsumasa Kuroi, Christian Marth, Bettina Müller, Seamus O'Reilly, Vincenzo Di Lauro, Andrea Gombos, et al.

Journal article  |  2018  |  The Lancet Oncology

BACKGROUND: In animal models of breast cancer, resistance to continuous use of letrozole can be reversed by withdrawal and reintro..

Reply to 'The St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017: the point of view of an International Panel of Experts in Radiation Oncology' by Kirova et al.

P Dubsky, G Curigliano, HJ Burstein, EP Winer, M Gnant, S Loibl, M Colleoni, MM Regan, M Piccart-Gebhart, H-J Senn, B Thürlimann, undefined Panel Members of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017, F André, J Baselga, J Bergh, H Bonnefoi, SY Brucker, F Cardoso, L Carey, E Ciruelos, et al.

Journal article  |  2018  |  Annals of Oncology

COOPERATIVE GROUPS: THE AUSTRALIAN PERSPECTIVE

Prudence A Francis, Katrin Sjoquist, Linda Mileshkin

Book Chapter  |  2018

Premenopausal women with early breast cancer treated with estradiol suppression have severely deteriorated bone microstructure

Sabashini K Ramchand, Ego Seeman, Xiao-Fang Wang, Ali Ghasem-Zadeh, Prudence A Francis, Evangeline J Ponnusamy, Michele S Bardin, Minh Bui, Roger Zebaze, Jeffrey D Zajac, Mathis Grossmann

Journal article  |  2017  |  Bone

Treatment Efficacy, Adherence, and Quality of Life Among Women Younger Than 35 Years in the International Breast Cancer Study Group TEXT and SOFT Adjuvant Endocrine Therapy Trials

Poornima Saha, Meredith M Regan, Olivia Pagani, Prudence A Francis, Barbara A Walley, Karin Ribi, Jurg Bernhard, Weixiu Luo, Henry L Gomez, Harold J Burstein, Vani Parmar, Roberto Torres, Josephine Stewart, Meritxell Bellet, Antonia Perello, Faysal Dane, Antonio Moreira, Daniel Vorobiof, Michelle Nottage, Karen N Price, et al.

Journal article  |  2017  |  Journal of Clinical Oncology

Concurrent and sequential initiation of ovarian function suppression with chemotherapy in premenopausal women with endocrine-responsive early breast cancer: an exploratory analysis of TEXT and SOFT

MM Regan, BA Walley, PA Francis, GF Fleming, I Lang, HL Gomez, M Colleoni, C Tondini, G Pinotti, M Salim, S Spazzapan, V Parmar, T Ruhstaller, EA Abdi, RD Gelber, AS Coates, A Goldhirsch, O Pagani

Journal article  |  2017  |  Annals of Oncology

De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017.

G Curigliano, HJ Burstein, EP Winer, M Gnant, P Dubsky, S Loibl, M Colleoni, MM Regan, M Piccart-Gebhart, H-J Senn, B Thürlimann, undefined St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017, F André, J Baselga, J Bergh, H Bonnefoi, SY Brucker, F Cardoso, L Carey, E Ciruelos, et al.

Journal article  |  2017  |  Annals of Oncology

The 15th St. Gallen International Breast Cancer Conference 2017 in Vienna, Austria reviewed substantial new evidence on loco-regio..

Adjuvant endocrine therapy for premenopausal women: Type and duration

Prudence A Francis

Journal article  |  2017  |  The Breast

Research needs in breast cancer

F Cardoso, N Harbeck, CH Barrios, J Bergh, J Cortes, N El Saghir, PA Francis, CA Hudis, S Ohno, AH Partridge, GW Sledge, IE Smith, KA Gelmon

Journal article  |  2017  |  Annals of Oncology

3rd ESO-ESMO international consensus guidelines for Advanced Breast Cancer (ABC 3).

F Cardoso, A Costa, E Senkus, M Aapro, F André, CH Barrios, J Bergh, G Bhattacharyya, L Biganzoli, MJ Cardoso, L Carey, D Corneliussen-James, G Curigliano, V Dieras, N El Saghir, A Eniu, L Fallowfield, D Fenech, P Francis, K Gelmon, et al.

Journal article  |  2017  |  The Breast

Dual HER2 Blockade

Christoph Thomssen, Nagi S El Saghir, Prudence A Francis, Jacek Jassem, Hope S Rugo, Michael Untch

Journal article  |  2017  |  Breast Care

3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3).

F Cardoso, A Costa, E Senkus, M Aapro, F André, CH Barrios, J Bergh, G Bhattacharyya, L Biganzoli, MJ Cardoso, L Carey, D Corneliussen-James, G Curigliano, V Dieras, N El Saghir, A Eniu, L Fallowfield, D Fenech, P Francis, K Gelmon, et al.

Journal article  |  2017  |  Annals of Oncology

Quality of Life Effects of Ovarian Suppression in the Suppression of Ovarian Function Trial Reply

Karin Ribi, Jurg Bernhard, Weixiu Luo, Meredith M Regan, Gini F Fleming, Prudence A Francis

Journal article  |  2016  |  Journal of Clinical Oncology

The Subclonal Architecture of Metastatic Breast Cancer: Results from a Prospective Community-Based Rapid Autopsy Program "CASCADE"

Peter Savas, Zhi Ling Teo, Christophe Lefevre, Christoffer Flensburg, Franco Caramia, Kathryn Alsop, Mariam Mansour, Prudence A Francis, Heather A Thorne, Maria Joao Silva, Nnennaya Kanu, Michelle Dietzen, Andrew Rowan, Maik Kschischo, Stephen Fox, David D Bowtell, Sarah-Jane Dawson, Terence P Speed, Charles Swanton, Sherene Loi

Journal article  |  2016  |  PLOS Medicine

Supportive care of women with breast cancer: key concerns and practical solutions

Nicholas Zdenkowski, Stephanie Tesson, Janine Lombard, Melanie Lovell, Sandra Hayes, Prudence A Francis, Haryana M Dhillon, Frances M Boyle

Journal article  |  2016  |  Medical Journal of Australia

Impact of CYP19A1 and ESR1 variants on early-onset side effects during combined endocrine therapy in the TEXT trial.

Harriet Johansson, Kathryn P Gray, Olivia Pagani, Meredith M Regan, Giuseppe Viale, Valentina Aristarco, Debora Macis, Antonella Puccio, Susanne Roux, Rudolf Maibach, Marco Colleoni, Manuela Rabaglio, Karen N Price, Alan S Coates, Richard D Gelber, Aron Goldhirsch, Roswitha Kammler, Bernardo Bonanni, Barbara A Walley, undefined the TEXT principal investigators

Journal article  |  2016  |  Breast Cancer Research

BACKGROUND: Single nucleotide polymorphisms (SNPs) in the estrogen receptor 1 (ESR1) and cytochrome P450 19A1 (CYP19A1) genes have..

A community-based model of rapid autopsy in end-stage cancer patients

Kathryn Alsop, Heather Thorne, Shahneen Sandhu, Anne Hamilton, Christopher Mintoff, Elizabeth Christie, Odette Spruyt, Scott Williams, Orla McNally, Linda Mileshkin, Sumitra Ananda, Julene Hallo, Sherene Loi, Clare Scott, Peter Savas, Lisa Devereux, Patricia O'Brien, Sameera Gunawardena, Clare Hampson, Kate Strachan, et al.

Journal article  |  2016  |  Nature Biotechnology

Absolute Benefit of Adjuvant Endocrine Therapies for Premenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer: TEXT and SOFT Trials

Meredith M Regan, Prudence A Francis, Olivia Pagani, Gini F Fleming, Barbara A Walley, Giuseppe Viale, Marco Colleoni, Istvan Lang, Henry L Gomez, Carlo Tondini, Graziella Pinotti, Karen N Price, Alan S Coates, Aron Goldhirsch, Richard D Gelber

Journal article  |  2016  |  Journal of Clinical Oncology

Are SOFT and TEXT results practice changing and how?

Olivia Pagani, Meredith M Regan, Prudence A Francis

Journal article  |  2016  |  The Breast

Twelve-Month Estrogen Levels in Premenopausal Women With Hormone Receptor-Positive Breast Cancer Receiving Adjuvant Triptorelin Plus Exemestane or Tamoxifen in the Suppression of Ovarian Function Trial (SOFT): The SOFT-EST Substudy

Meritxell Bellet, Kathryn P Gray, Prudence A Francis, Istvan Lang, Eva Ciruelos, Ana Lluch, Miguel Angel Climent, Gustavo Catalan, Antoni Avella, Uriel Bohn, Antonio Gonzalez-Martin, Roser Ferrer, Roberto Catalan, Analia Azaro, Agnita Rajasekaran, Josefa Morales, Josep Vazquez, Gini F Fleming, Karen N Price, Meredith M Regan

Journal article  |  2016  |  Journal of Clinical Oncology

Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function Trial

Karin Ribi, Weixiu Luo, Jurg Bernhard, Prudence A Francis, Harold J Burstein, Eva Ciruelos, Meritxell Bellet, Lorenzo Pavesi, Ana Lluch, Marilena Visini, Vani Parmar, Carlo Tondini, Pierre Kerbrat, Antonia Perello, Patrick Neven, Roberto Torres, Davide Lombardi, Fabio Puglisi, Per Karlsson, Thomas Ruhstaller, et al.

Journal article  |  2016  |  Journal of Clinical Oncology

Adjuvant ovarian function suppression and cognitive function in women with breast cancer

Kelly-Anne Phillips, Meredith M Regan, Karin Ribi, Prudence A Francis, Fabio Puglisi, Meritxell Bellet, Simon Spazzapan, Per Karlsson, Daniel R Budman, Khalil Zaman, Ehtesham A Abdi, Susan M Domchek, Yang Feng, Karen N Price, Alan S Coates, Richard D Gelber, Paul Maruff, Frances Boyle, John F Forbes, Tim Ahles, et al.

Journal article  |  2016  |  British Journal of Cancer

Predictive value and clinical utility of centrally assessed ER, PgR, and Ki-67 to select adjuvant endocrine therapy for premenopausal women with hormone receptor-positive, HER2-negative early breast cancer: TEXT and SOFT trials

Meredith M Regan, Olivia Pagani, Prudence A Francis, Gini F Fleming, Barbara A Walley, Roswitha Kammler, Patrizia Dell'Orto, Leila Russo, Janos Szoke, Franco Doimi, Laura Villani, Stefano Pizzolitto, Christian Oehlschlegel, Fausto Sessa, Vicente Peg Camara, Jose Luis Rodriguez Peralto, Gaetan MacGrogan, Marco Colleoni, Aron Goldhirsch, Karen N Price, et al.

Journal article  |  2015  |  Breast Cancer Research and Treatment

Final 10-year results of the Breast International Group 2-98 phase III trial and the role of Ki67 in predicting benefit of adjuvant docetaxel in patients with oestrogen receptor positive breast cancer

Amir Sonnenblick, Prudence A Francis, Hatem A Azim, Evandro de Azambuja, Bo Nordenskjold, Jorge Gutierez, Emmanuel Quinaux, Mauro G Mastropasqua, Lieveke Ameye, Michael Anderson, Ana Lluch, Michael Gnant, Aron Goldhirsch, Angelo Di Leo, Agusti Barnadas, Hernan Cortes-Funes, Martine Piccart, John Crown

Journal article  |  2015  |  European Journal of Cancer

Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials

Juerg Bernhard, Weixiu Luo, Karin Ribi, Marco Colleoni, Harold J Burstein, Carlo Tondini, Graziella Pinotti, Simon Spazzapan, Thomas Ruhstaller, Fabio Puglisi, Lorenzo Pavesi, Vani Parmar, Meredith M Regan, Olivia Pagani, Gini F Fleming, Prudence A Francis, Karen N Price, Alan S Coates, Richard D Gelber, Aron Goldhirsch, et al.

Journal article  |  2015  |  The Lancet Oncology

Adjuvant Ovarian Suppression in Premenopausal Breast Cancer REPLY

Prudence A Francis, Meredith M Regan, Gini F Fleming

Journal article  |  2015  |  New England Journal of Medicine

Goserelin for Ovarian Protection during Breast-Cancer Adjuvant Chemotherapy

Halle CF Moore, Joseph M Unger, Kelly-Anne Phillips, Frances Boyle, Erika Hitre, David Porter, Prudence A Francis, Lori J Goldstein, Henry L Gomez, Carlos S Vallejos, Ann H Partridge, Shaker R Dakhil, Agustin A Garcia, Julie Gralow, Janine M Lombard, John F Forbes, Silvana Martino, William E Barlow, Carol J Fabian, Lori Minasian, et al.

Journal article  |  2015  |  New England Journal of Medicine

Adjuvant Ovarian Suppression in Premenopausal Breast Cancer

Prudence A Francis, Meredith M Regan, Gini F Fleming, Istvan Lang, Eva Ciruelos, Meritxell Bellet, Herve R Bonnefoi, Miguel A Climent, Gian Antonio Da Prada, Harold J Burstein, Silvana Martino, Nancy E Davidson, Charles E Geyer, Barbara A Walley, Robert Coleman, Pierre Kerbrat, Stefan Buchholz, James N Ingle, Eric P Winer, Manuela Rabaglio-Poretti, et al.

Journal article  |  2015  |  New England Journal of Medicine

ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)†.

F Cardoso, A Costa, L Norton, E Senkus, M Aapro, F André, CH Barrios, J Bergh, L Biganzoli, KL Blackwell, MJ Cardoso, T Cufer, N El Saghir, L Fallowfield, D Fenech, P Francis, K Gelmon, SH Giordano, J Gligorov, A Goldhirsch, et al.

Journal article  |  2014  |  Annals of Oncology

Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer

Olivia Pagani, Meredith M Regan, Barbara A Walley, Gini F Fleming, Marco Colleoni, Istvan Lang, Henry L Gomez, Carlo Tondini, Harold J Burstein, Edith A Perez, Eva Ciruelos, Vered Stearns, Herve R Bonnefoi, Silvana Martino, Charles E Geyer, Graziella Pinotti, Fabio Puglisi, Diana Crivellari, Thomas Ruhstaller, Eric P Winer, et al.

Journal article  |  2014  |  New England Journal of Medicine

Systemic treatment of HER2 metastatic breast cancer: Clinical conundrums and future perspectives

Richard De Boer, Jane Beith, Jacquie Chirgwin, Sue Chua, Maree Colosimo, Prudence Francis, Michael Green, Ken Pittman, Michelle White, Nicholas Wilcken, Nicholas Zdenkowski, Richard Bell

Journal article  |  2014  |  Asia-Pacific Journal of Clinical Oncology

Systemic treatment of HER2-positive metastatic breast cancer: A systematic review

Nicholas Wilcken, Nicholas Zdenkowski, Michelle White, Ray Snyder, Ken Pittman, Paul Mainwaring, Michael Green, Prudence Francis, Richard De Boer, Maree Colosimo, Sue Chua, Jacquie Chirgwin, Jane Beith, Richard Bell

Journal article  |  2014  |  Asia-Pacific Journal of Clinical Oncology

Neoadjuvant chemotherapy with sequential anthracycline-docetaxel with gemcitabine for large operable or locally advanced breast cancer: ANZ 0502 (NeoGem)

N McCarthy, F Boyle, N Zdenkowski, J Bull, E Leong, A Simpson, G Kannourakis, PA Francis, J Chirgwin, E Abdi, V Gebski, AS Veillard, D Zannino, N Wilcken, L Reaby, DF Lindsay, HD Badger, JF Forbes

Journal article  |  2014  |  The Breast

Exemestane with varian suppression in premenopausal Breast Cancer

O Pagani, MM Regan, PA Francis

Journal article  |  2014  |  New England Journal of Medicine

Adjuvant treatment of premenopausal women with endocrine-responsive early breast cancer: Design of the TEXT and SOFT trials

Meredith M Regan, Olivia Pagani, Gini F Fleming, Barbara A Walley, Karen N Price, Manuela Rabaglio, Rudolf Maibach, Barbara Ruepp, Alan S Coates, Aron Goldhirsch, Marco Colleoni, Richard D Gelber, Prudence A Francis

Journal article  |  2013  |  The Breast

International guidelines for management of metastatic breast cancer (MBC) from the European School of Oncology (ESO)-MBC Task Force: Surveillance, staging, and evaluation of patients with early-stage and metastatic breast cancer

Nancy U Lin, Christoph Thomssen, Fatima Cardoso, David Cameron, Tanja Cufer, Lesley Fallowfield, Prudence A Francis, Stella Kyriakides, Olivia Pagani, Elzbieta Senkus, Alberto Costa, Eric P Winer

Journal article  |  2013  |  BREAST

Overall survival benefit for sequential doxorubicin-docetaxel compared with concurrent doxorubicin and docetaxel in node-positive breast cancer-8-year results of the Breast International Group 02-98 phase III trial

C Oakman, PA Francis, J Crown, E Quinaux, M Buyse, E De Azambuja, M Margeli Vila, M Andersson, B Nordenskjold, R Jakesz, B Thuerlimann, J Gutierrez, V Harvey, L Punzalan, P Dell'Orto, D Larsimont, I Steinberg, RD Gelber, M Piccart-Gebhart, G Viale, et al.

Journal article  |  2013  |  ANNALS OF ONCOLOGY

Prognostic and Predictive Value of Tumor-Infiltrating Lymphocytes in a Phase III Randomized Adjuvant Breast Cancer Trial in Node-Positive Breast Cancer Comparing the Addition of Docetaxel to Doxorubicin With Doxorubicin-Based Chemotherapy: BIG 02-98

Sherene Loi, Nicolas Sirtaine, Fanny Piette, Roberto Salgado, Giuseppe Viale, Francoise Van Eenoo, Ghizlane Rouas, Prudence Francis, John PA Crown, Erika Hitre, Evandro de Azambuja, Emmanuel Quinaux, Angelo Di Leo, Stefan Michiels, Martine J Piccart, Christos Sotiriou

Journal article  |  2013  |  JOURNAL OF CLINICAL ONCOLOGY

1st International consensus guidelines for advanced breast cancer (ABC 1)

F Cardoso, A Costa, L Norton, D Cameron, T Cufer, L Fallowfield, P Francis, J Gligorov, S Kyriakides, N Lin, O Pagani, E Senkus, C Thomssen, M Aapro, J Bergh, A Di Leo, N El Saghir, PA Ganz, K Gelmon, A Goldhirsch, et al.

Journal article  |  2012  |  The Breast

Strategies for the discovery and development of therapies for metastatic breast cancer

Bedrich L Eckhardt, Prudence A Francis, Belinda S Parker, Robin L Anderson

Journal article  |  2012  |  Nature Reviews Drug Discovery

Adjuvant Trastuzumab in HER2-Positive Breast Cancer

Ian Collins, Prudence Francis, Linda Mileshkin

Journal article  |  2012  |  New England Journal of Medicine

Docetaxel pharmacokinetics and its correlation with two in vivo probes for cytochrome P450 enzymes: the C-14-erythromycin breath test and the antipyrine clearance test

M Michael, C Cullinane, A Hatzimihalis, C O'Kane, A Milner, R Booth, S Schlicht, SJ Clarke, P Francis

Journal article  |  2012  |  Cancer Chemotherapy and Pharmacology

Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trial

Lynnette Fernandez-Cuesta, Catherine Oakman, Priscila Falagan-Lotsch, Ke-seay Smoth, Emmanuel Quinaux, Marc Buyse, M Stella Dolci, Evandro De Azambuja, Pierre Hainaut, Patrizia Dell'Orto, Denis Larsimont, Prudence A Francis, John Crown, Martine Piccart-Gebhart, Giuseppe Viale, Angelo Di Leo, Magali Olivier

Journal article  |  2012  |  Breast Cancer Research

Capecitabine Versus Classical Cyclophosphamide, Methotrexate, and Fluorouracil As First-Line Chemotherapy for Advanced Breast Cancer

Martin R Stockler, Vernon J Harvey, Prudence A Francis, Michael J Byrne, Stephen P Ackland, Bernie Fitzharris, Guy Van Hazel, Nicholas RC Wilcken, Peter S Grimison, Anna K Nowak, M Corona Gainford, Akiko Fong, Lisa Paksec, Tatiana Sourjina, Diana Zannino, Val Gebski, R John Simes, John F Forbes, Alan S Coates

Journal article  |  2011  |  Journal of Clinical Oncology

Legionella pneumophila lung abscess associated with immune suppression

SD Guy, LJ Worth, KA Thursky, PA Francis, MA Slavin

Journal article  |  2011  |  Internal Medicine Journal

Optimal adjuvant therapy for very young breast cancer patients

Prudence A Francis

Journal article  |  2011  |  The Breast

Rational use of trastuzumab in metastatic and locally advanced breast cancer: Implications of recent research

Shorn Goel, Jacquie Chirgwin, Prudence Francis, Robin Stuart-Harris, Joanna Dewar, Linda Mileshkin, Ray Snyder, Michael Michael, Bogda Koczwara

Journal article  |  2011  |  The Breast Journal

Tamoxifen, cytochrome P450 genes and breast cancer clinical outcomes

Madhu S Singh, Prudence A Francis, Michael Michael

Journal article  |  2011  |  The Breast Journal

The effect of body mass index on overall and disease-free survival in node-positive breast cancer patients treated with docetaxel and doxorubicin-containing adjuvant chemotherapy: the experience of the BIG 02-98 trial

Evandro de Azambuja, Worta McCaskill-Stevens, Prudence Francis, Emmanuel Quinaux, John PA Crown, Malou Vicente, Rosa Giuliani, Bo Nordenskjold, Jorge Gutierez, Michael Andersson, Mireia Margeli Vila, Raimund Jakesz, Jan Demol, Joanna Dewar, Armando Santoro, Ana Lluch, Steven Olsen, Richard D Gelber, Angelo Di Leo, Martine Piccart-Gebhart

Journal article  |  2010  |  Breast Cancer Research and Treatment

Gefitinib treatment in hormone-resistant and hormone receptor-negative advanced breast cancer

MD Green, PA Francis, V Gebski, V Harvey, C Karapetis, A Chan, R Snyder, A Fong, R Basser, JF Forbes

Journal article  |  2009  |  Annals of Oncology

Young Patients with Breast Cancer

PA Francis

Book  |  2009  |  Cancer Treatment and Research

Surprised by Hope

Prudence A Francis

Journal article  |  2008  |  JOURNAL OF CLINICAL ONCOLOGY

Is risk of central nervous system (CNS) relapse related to adjuvant taxane treatment in node-positive breast cancer? Results of the CNS substudy in the intergroup phase III BIG 02-98 trial

BC Pestalozzi, P Francis, E Quinaux, S Dolci, E Azambuja, RD Gelber, G Viale, A Balil, M Andersson, B Nordenskjoeld, M Gnant, J Gutierrez, I Lang, JPA Crown, M Piccart-Gebhart

Journal article  |  2008  |  ANNALS OF ONCOLOGY

Premenopausal endocrine-responsive early breast cancer: who receives chemotherapy?

MM Regan, O Pagani, B Walley, R Torrisi, EA Perez, P Francis, GF Fleming, KN Price, B Thuerlimann, R Maibach, M Castiglione-Gertsch, AS Coates, A Goldhirsch, RD Gelber

Journal article  |  2008  |  ANNALS OF ONCOLOGY

Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials

GF Fleming, P Francis

Journal article  |  2008  |  Breast Diseases: A Year Book Quarterly

Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial

Prudence Francis, John Crown, Angelo Di Leo, Marc Buyse, Ana Balil, Michael Andersson, Bo Nordenskjold, Istvan Lang, Raimund Jakesz, Daniel Vorobiof, Jorge Gutierrez, Guy van Hazel, Stella Dolci, Sophie Jamin, Belguendouz Bendahmane, Richard D Gelber, Aron Goldhirsch, Monica Castiglione-Gertsch, Martine Piccart-Gebhart

Journal article  |  2008  |  JOURNAL OF THE NATIONAL CANCER INSTITUTE

1-60 Adjuvant goserelin in pre-menopausal patients with early breast cancer: Results from the ZIPP study

GF Fleming, P Francis

Journal article  |  2007  |  Breast Diseases: A Year Book Quarterly

Central nervous system metastases in women with HER-2 positive metastatic breast cancer after treatment with trastuzumab

SJ Dawson, NF Ranieri, RD Snyder, SA McLachlan, WI Burns, GM Newnham, PA Francis, AJ Dowling

Journal article  |  2006  |  Asia-Pacific Journal of Clinical Oncology

Self reported morbidity and awareness regarding common cancers in elderly women.

S Aswathy, S Sumithra, LS Valsala, S Sandheep, V Lohidas, P Shobha, S George, P Francis, NS Rajeev, AJ Johnson

Journal article  |  2006  |  Journal of Communicable Diseases

A study based on 198 women above 45 years of age was undertaken using interview methods in a house to house survey, to find the se..

Isolex 300i CD34-selected cells to support multiple cycles of high-dose therapy

HM Prince, J Bashford, D Wall, D Rischin, N Parker, GC Toner, JF Seymour, D Blakey, D Haylock, P Simmons, P Francis, M Wolf, EH Januszewicz, G Richardson, J Scarlett, P Briggs

Journal article  |  2002  |  Cytotherapy

Taxanes as adjuvant for breast cancer.

A Goldhirsch, P Francis, M Castiglione-Gertsch, RD Gelber, AS Coates

Journal article  |  2000  |  The Lancet

Repetitive high-dose therapy with ifosfamide, thiotepa and paclitaxel with peripheral blood progenitor cell and filgrastim support for metastatic and locally advanced breast cancer: Results of a phase I study

HM Prince, MJ Millward, D Rischin, D Blakey, P Francis, P Gates, P Chapple, M Quinn, S Juneja, M Wolf, EH Januszewicz, JF Seymour, M Brettell, A Strickland, J Zalcberg, G Richardson, J Scarlett, P Briggs, GC Toner

Journal article  |  1999  |  Annals of Oncology

Ifosfamide in combination with paclitaxel or doxorubicin: regimens which effectively mobilize peripheral blood progenitor cells while demonstrating anti-tumor activity in patients with metastatic breast cancer

HM Prince, J Gardyn, MJ Millward, D Rischin, P Francis, P Gates, P Chapple, M Quinn, S Juneja, M Wolf, EH Januszewicz, G Richardson, J Scarlett, P Briggs, M Brettell, GC Toner

Journal article  |  1999  |  Bone Marrow Transplantation

A phase I and pharmacokinetic study of paclitaxel and epirubicin in advanced cancer.

D Rischin, LK Webster, MJ Millward, GC Toner, S Nawaratne, V Ganju, P Francis, JF Bishop

Journal article  |  1999  |  Investigational New Drugs

The objectives of this phase I trial were to determine the maximally tolerated doses of the combination of epirubicin and paclitax..

Phase II trials of docetaxel (Taxotere) in advanced ovarian cancer--an updated overview.

SB Kaye, M Piccart, M Aapro, P Francis, J Kavanagh

Journal article  |  1997  |  European Journal of Cancer

Docetaxel (Taxotere) has been studied at a dose of 100 mg/m2 i.v. as a one hour infusion every 3 weeks, in four phase II trials in..

Activity and toxicity of docetaxel (Taxotere) in women with previously treated metastatic breast cancer.

JD Shapiro, MJ Millward, D Rischin, JD Davison, M Michael, PA Francis, V Ganju, GC Toner

Journal article  |  1997  |  Australian and New Zealand Journal of Medicine

BACKGROUND: Metastatic breast cancer is a major cause of cancer death in Australian women. Docetaxel is a new cytotoxic drug that ..

Activity of gemcitabine in patients with advanced ovarian cancer: responses seen following platinum and paclitaxel.

JD Shapiro, MJ Millward, D Rischin, M Michael, V Walcher, PA Francis, GC Toner

Journal article  |  1996  |  Gynecologic Oncology

Thirty-eight women with epithelial ovarian cancer were treated with gemcitabine, a new antimetabolite. All had previously received..

Ninety-six-hour paclitaxel infusion after progression during short taxane exposure: a phase II pharmacokinetic and pharmacodynamic study in metastatic breast cancer.

AD Seidman, D Hochhauser, M Gollub, B Edelman, TJ Yao, CA Hudis, P Francis, D Fennelly, TA Gilewski, ME Moynahan, V Currie, J Baselga, W Tong, M O'Donaghue, R Salvaggio, L Auguste, D Spriggs, L Norton

Journal article  |  1996  |  Journal of Clinical Oncology

PURPOSE: A phase II trial of paclitaxel infused over 96 hours in patients with metastatic breast cancer with demonstrated disease ..

Phase I feasibility and pharmacologic study of weekly intraperitoneal paclitaxel: a Gynecologic Oncology Group pilot Study.

P Francis, E Rowinsky, J Schneider, T Hakes, W Hoskins, M Markman

Journal article  |  1995  |  Journal of Clinical Oncology

PURPOSE: This study was designed to define the maximum-tolerated dose (MTD) and pharmacology of paclitaxel administered by the int..

Intraperitoneal paclitaxel: a possible role in the management of ovarian cancer?

M Markman, P Francis, E Rowinsky, W Hoskins

Conference Proceedings  |  1995  |  Seminars in Oncology

Intraperitoneal paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) has been examined for a potential role in the mana..

Paclitaxel (Taxol) and docetaxel (Taxotere): active chemotherapeutic agents in lung cancer.

PA Francis, MG Kris, JR Rigas, SC Grant, VA Miller

Journal article  |  1995  |  Lung Cancer

Paclitaxel (Taxol), the prototype of a new class of plant-derived antineoplastic compounds, is a natural product isolated from the..

Phase II trial of a 75-mg/m2 dose of docetaxel with prednisone premedication for patients with advanced non-small cell lung cancer.

VA Miller, JR Rigas, PA Francis, SC Grant, KM Pisters, ES Venkatraman, K Woolley, RT Heelan, MG Kris

Journal article  |  1995  |  Cancer

BACKGROUND: A prior Phase II study of a 100-mg/m2 dose of docetaxel conducted at the Memorial Sloan-Kettering Cancer Center (New Y..

Clinical and pharmacology study of chloroquinoxaline sulfonamide given on a weekly schedule.

JR Rigas, PA Francis, VA Miller, WP Tong, N Roistacher, MG Kris, JP Orazem, CW Young, RP Warrell

Journal article  |  1995  |  Cancer Chemotherapy and Pharmacology

The in vitro human tumor colony-forming assay identified chloroquinoxaline sulfonamide (CQS) as an active agent at human plasma co..

Phase II trial of docetaxel in patients with platinum-refractory advanced ovarian cancer.

P Francis, J Schneider, L Hann, C Balmaceda, R Barakat, M Phillips, T Hakes

Journal article  |  1994  |  Journal of Clinical Oncology

PURPOSE: This phase II study was conducted to evaluate the efficacy and toxicity of docetaxel in the treatment of patients with pl..

Phase II trial of docetaxel in patients with stage III and IV non-small-cell lung cancer.

PA Francis, JR Rigas, MG Kris, KM Pisters, JP Orazem, KJ Woolley, RT Heelan

Journal article  |  1994  |  Journal of Clinical Oncology

PURPOSE: This phase II study was conducted to evaluate the efficacy and toxicity of docetaxel in the treatment of patients with ad..

Intraperitoneal Taxol (paclitaxel) in the management of ovarian cancer.

M Markman, P Francis, E Rowinsky, T Hakes, B Reichman, W Jones, JL Lewis, S Rubin, J Curtin, R Barakat

Journal article  |  1994  |  Annals of oncology : official journal of the European Society for Medical Oncology / ESMO

In an effort to examine the safety and pharmacology of the intraperitoneal (i.p.) delivery of paclitaxel, 25 patients (24 with ova..

Constitutive variability in the pharmacokinetics of the natural retinoid, all-trans-retinoic acid, and its modulation by ketoconazole.

JR Rigas, PA Francis, JR Muindi, MG Kris, C Huselton, F DeGrazia, JP Orazem, CW Young, RP Warrell

Journal article  |  1993  |  JNCI Journal of the National Cancer Institute

BACKGROUND: All-trans-retinoic acid (all-trans RA) induces complete remission in most patients with acute promyelocytic leukemia (..

High-intensity chemotherapy with hematopoietic support in breast cancer.

J Crown, L Vahdat, D Fennelly, P Francis, C Wasserheit, C Hudis, A Kritz, J Schneider, N Hamilton, T Gilewski

Conference Proceedings  |  1993  |  Annals of the New York Academy of Sciences

Chemotherapy can produce excellent palliation for many patients with metastatic breast cancer. Survival impact is, however, limite..

Diethyldithiocarbamate chemoprotection of carboplatin--induced hematological toxicity.

P Francis, M Markman, T Hakes, B Reichman, S Rubin, W Jones, JL Lewis, J Curtin, R Barakat, M Phillips

Journal article  |  1993  |  Journal of Cancer Research and Clinical Oncology

Carboplatin therapy has a more favorable toxicity profile than cisplatin and, given in appropriate doses, is equivalent in efficac..

Evaluation of an inhibition enzyme immunoassay kit for mammary serum antigen (MSA)

GT Layton, J Golder, S Johnston, MA McGuckin, B Ward, T Lo, P Williams, JF Bishop, P Jeal, P Francis, PX Xing, IFC McKenzie

Journal article  |  1991  |  Journal of Tumor Marker Oncology

Epilepsy and photosensitivity.

H Aziz, P Francis, SM Ali, Z Hasan

Journal article  |  1989  |  Journal of the Pakistan Medical Association

In a series of 2053 cases of epilepsy studied 3.9% were found to have some form of photosensitive epilepsy. The mean age of onset ..